Clinical Trial: A prospective, single-arm, multicenter clinical study on the reinitiation of tofacitinib combined with immune checkpoint inhibitors in patients with previously resolved immune-related adverse events (irAEs) (China)

China, Oct. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, single-arm, multicenter clinical study on the reinitiation of tofacitinib combined with immune checkpoint inhibitors in patients with previously resolved immune-related adverse events (irAEs)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134216

Registration Time: 2026/10/12

Type: Interventional study

Primary Sponsor: Fujian Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=346684

Published by HT Digital Content Services with permission from Health Daily Digest....